Biofrontera Challenges Sun Pharma Patent for Skin Treatment

Biofrontera filed a petition with the U.S. Patent Trial and Appeal Board seeking to cancel patent 10,357,567 owned by Sun Pharma’s Dusa.

• Companies have competing treatments for actinic keratosis, a pre-cancerous skin condition
• Biofrontera contends the patent covers “a common off-label use” of the therapy “that was already employed by researchers and doctors in the field for more than a decade”
• Dusa has accused Biofrontera of stealing secrets and infringing other patents in case pending in Boston
• NOTE: PTAB will take a preliminary look at Biofrontera’s petition and any response from Dusa; board will conduct a further review if ...